4,901 trials
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 1; 4; 1; 3 participants
Alzheimer's Disease
Primary: Florbetapir SUVr Conversion to Centiloid Units — 82.44; 50.75; 81.19; 14.93 centiloid
Healthy
Primary: AUC0-tz of Empagliflozin in Plasma — 2190; 2210 nmol*h/L — p=<0.0001
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin — 2630…
Metastatic Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of TAK-117 — 150; 900; 900; NA mg
Healthy
Primary: AUC0-tz of Empagliflozin in Plasma — 5370; 5470 nmol·h/L — p=<0.00001
Plaque Psoriasis
Primary: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 — 114.2; 110.6; 108.7; 102.8 millimeter of mercury (mmHg)
Healthy
Primary: Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin — 6430…
Type 1 Diabetes Mellitus
Primary: Comparison of MK-1293 and EU-Approved Lantus Duration of Pharmacodynamic Action During a 30-Hour Euglycemic Clamp Study — 30; 30 Hours
Locally Advanced Solid Tumor · Metastatic Solid Tumor · Breast Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 subjects
Solid Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A — 0; 0; 0; 0 subjects
Healthy
Primary: Overall Palatability Visual Analogue Scale (VAS) Score at 0 Minute (Right After the Spit-out of the Investigational Medicinal Product [IMP]) — 49.0; 39.3; 67.5; 51.4…
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Primary: Cmax of AZD9291 After Single Dosing — 103.8; 195.9 nmol/L
Advanced Adult Hepatocellular Carcinoma · Hepatocellular Carcinoma Metastatic
Primary: Number of Participants With Dose Limiting Toxicities During Cycle 1 — 0; 1; 1; 2 participants with DLT
Helicobacter Pylori Infection
Primary: The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo. — 0; 0; 21; 8 Percentage of subjects